Adults aged 80 and older with early-stage lung cancer can safely undergo surgery and achieve outcomes comparable to younger patients, challenging longstanding assumptions about age and cancer treatment, according to a study led by researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center.
A head-to-head comparison of five leading treatments for anaplastic lymphoma kinase-positive non-small cell lung cancer could help oncologists fine-tune first-line TKI selection beyond what’s been seen in clinical trials alone, according to a study conducted by a team of researchers from the Keck School of Medicine of USC, the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences and the USC Shaeffer Center for Health Policy & Economics have conducted.
